Abstract
Breast cancer is a heterogeneous disease with a complex etiology that develops from different cellular lineages, progresses along multiple molecular pathways, and demonstrates wide variability in response to treatment. The “standard of care” approach to breast cancer treatment in which all patients receive similar interventions is rapidly being replaced by personalized medicine, based on molecular characteristics of individual patients. Both inherited and somatic genomic variation is providing useful information for customizing treatment regimens for breast cancer to maximize efficacy and minimize adverse side effects. In this article, we review (1) hereditary breast cancer and current use of inherited susceptibility genes in patient management; (2) the potential of newly-identified breast cancer-susceptibility variants for improving risk assessment; (3) advantages and disadvantages of direct-to-consumer testing; (4) molecular characterization of sporadic breast cancer through immunohistochemistry and gene expression profiling and opportunities for personalized prognostics; and (5) pharmacogenomic influences on the effectiveness of current breast cancer treatments. Molecular genomics has the potential to revolutionize clinical practice and improve the lives of women with breast cancer.
Keywords: Breast cancer, personal genomics, genetic tests, gene expression, risk assessment
Current Genomics
Title: Breast Cancer in the Personal Genomics Era
Volume: 11 Issue: 3
Author(s): Rachel E. Ellsworth, David J. Decewicz, Craig D. Shriver and Darrell L. Ellsworth
Affiliation:
Keywords: Breast cancer, personal genomics, genetic tests, gene expression, risk assessment
Abstract: Breast cancer is a heterogeneous disease with a complex etiology that develops from different cellular lineages, progresses along multiple molecular pathways, and demonstrates wide variability in response to treatment. The “standard of care” approach to breast cancer treatment in which all patients receive similar interventions is rapidly being replaced by personalized medicine, based on molecular characteristics of individual patients. Both inherited and somatic genomic variation is providing useful information for customizing treatment regimens for breast cancer to maximize efficacy and minimize adverse side effects. In this article, we review (1) hereditary breast cancer and current use of inherited susceptibility genes in patient management; (2) the potential of newly-identified breast cancer-susceptibility variants for improving risk assessment; (3) advantages and disadvantages of direct-to-consumer testing; (4) molecular characterization of sporadic breast cancer through immunohistochemistry and gene expression profiling and opportunities for personalized prognostics; and (5) pharmacogenomic influences on the effectiveness of current breast cancer treatments. Molecular genomics has the potential to revolutionize clinical practice and improve the lives of women with breast cancer.
Export Options
About this article
Cite this article as:
E. Ellsworth Rachel, J. Decewicz David, D. Shriver Craig and L. Ellsworth Darrell, Breast Cancer in the Personal Genomics Era, Current Genomics 2010; 11 (3) . https://dx.doi.org/10.2174/138920210791110951
DOI https://dx.doi.org/10.2174/138920210791110951 |
Print ISSN 1389-2029 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5488 |
Call for Papers in Thematic Issues
Advanced AI Techniques in Big Genomic Data Analysis
The thematic issue on "Advanced AI Techniques in Big Genomic Data Analysis" aims to explore the cutting-edge methodologies and applications of artificial intelligence (AI) in the realm of genomic research, where vast amounts of data pose both challenges and opportunities. This issue will cover a broad spectrum of AI-driven strategies, ...read more
Genomic Insights into Oncology: Harnessing Machine Learning for Breakthroughs in Cancer Genomics.
This special issue aims to explore the cutting-edge intersection of genomics and oncology, with a strong emphasis on original data and experimental validation. While maintaining the focus on how machine learning and advanced data analysis techniques are revolutionizing our understanding and treatment of cancer, this issue will prioritize contributions that ...read more
Integrating Artificial Intelligence and Omics Approaches in Complex Diseases
Recent advancements in AI and omics methodologies have revolutionized the landscape of biomedical research, enabling us to extract valuable information from vast amounts of complex data. By combining AI algorithms with omics technologies such as genomics, proteomics, metabolomics, and transcriptomics, researchers can obtain a more comprehensive and multi-dimensional analysis of ...read more
Integrating Machine Learning with Genome Science: Pioneering Developments and Future Directions
Integrating machine learning (ML) with genome science is driving transformative advancements in fields such as genomics, personalized medicine, and drug discovery. Genomic data is vast and complex, making traditional analysis methods inadequate for uncovering deep insights. Machine learning, particularly deep learning models like convolutional neural networks (CNNs) and recurrent neural ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
A Neuroinformatics Study Describing Molecular Interaction of Cisplatin with Acetylcholinesterase: A Plausible Cause for Anticancer Drug Induced Neurotoxicity
CNS & Neurological Disorders - Drug Targets Design of multifunctional nanocarriers for delivery of anti-cancer therapy
Current Pharmaceutical Design New Organ-Specific Drug Strategies Interfering in Signaling Pathways: Kinase Inhibitors and Other New Developmental Drugs in HCC
Current Signal Transduction Therapy Histone Deacetylase Inhibitors: Molecular and Biological Activity as a Premise to Clinical Application
Current Drug Metabolism Polymeric Nanocarriers: A New Horizon for the Effective Management of Breast Cancer
Current Pharmaceutical Design Futibatinib: A Potent and Irreversible Inhibitor of Fibroblast Growth Factor Receptors for Treatment of the Bile Duct Cancer
Current Medicinal Chemistry Drug Tissue Distribution: Study Methods and Therapeutic Implications
Current Pharmaceutical Design Clinical Efficacy and Effectiveness of Ursodeoxycholic Acid in Cholestatic Liver Diseases
Current Clinical Pharmacology Drug Delivery Across the Blood-Brain Barrier
Current Drug Delivery ErbB Targeted Drugs and Angiogenesis
Current Vascular Pharmacology PDGF-D Signaling: A Novel Target in Cancer Therapy
Current Drug Targets Targeting Established Tumor Vasculature: A Novel Approach to Cancer Treatment
Current Cancer Therapy Reviews Bispecific Antibodies: An Innovative Arsenal to Hunt, Grab and Destroy Cancer Cells
Current Pharmaceutical Biotechnology Medicinal Chemistry of Antiviral/Anticancer Prodrugs Subjected to Phosphate Conjugation
Mini-Reviews in Medicinal Chemistry Effect of Inhibitors of Nitric Oxide in Animal Models and Future Directions for Therapy in Inflammatory Disorders
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Inhibitory Effect of Hydroxysafflor Yellow B on the Proliferation of Human Breast Cancer MCF-7 Cells
Recent Patents on Anti-Cancer Drug Discovery Histone Deacetylase Inhibitors: An Attractive Strategy for Cancer Therapy
Current Medicinal Chemistry Editorial ( Thematic Issue: Diabetes and Cancer - Disease, Drugs or Deception?)
Current Drug Safety Epigenetic Regulation of Epithelial-Mesenchymal Transition by Hypoxia in Cancer: Targets and Therapy
Current Pharmaceutical Design Antioxidant Effects and in vitro Cytotoxicity on Human Cancer Cell Lines of Flavonoid-Rich Flamboyant (<i>Delonix regia</i> (Bojer) Raf.) Flower Extract
Current Pharmaceutical Biotechnology